Cardioprotection by ε-Protein Kinase C Activation From Ischemia: Continuous Delivery and Antiarrhythmic Effect of an ε-Protein Kinase C-Activating Peptide
Open accessThe DOI matches its Crossref record.
Abstract
Background— We previously showed that a selective activator peptide of ε-protein kinase C (PKC), ψεRACK, conferred cardioprotection against ischemia-reperfusion when delivered ex vivo before the ischemic event. Here, we tested whether in vivo continuous systemic delivery of ψεRACK confers sustained cardioprotection against ischemia-reperfusion in isolated mouse hearts and whether ψεRACK treatment reduces infarct size or lethal arrhythmias in porcine hearts in vivo. Methods and Results— After ψεRACK was systemically administered in mice either acutely or continuously, hearts were subjected to ischemia-reperfusion in an isolated perfused model. Whereas ψεRACK-induced cardioprotection lasted 1 hour after a single intraperitoneal injection, continuous treatment with ψεRACK induced a sustained preconditioned state during the 10 days of delivery. There was no desensitization to the therapeutic effect, no downregulation of εPKC, and no adverse effects after sustained ψεRACK delivery. Porcine hearts were subjected to ischemia-reperfusion in vivo, and ψεRACK was administered by intracoronary injection during the first 10 minutes of ischemia. ψεRACK treatment reduced infarct size (34±2% versus 14±1%, control versus ψεRACK) and resulted in fewer cases of ventricular fibrillation during ischemia-reperfusion (87.5% versus 50%, control versus ψεRACK). Conclusions— The εPKC activator ψεRACK induced cardioprotection both in vivo and ex vivo, reduced the incidence of lethal arrhythmia during ischemia-reperfusion, and did not cause desensitization or downregulation of εPKC after sustained delivery. Thus, ψεRACK may be useful for patients with ischemic heart disease. In addition, the ψεRACK peptide should be a useful pharmacological agent for animal studies in which systemic and sustained modulation of εPKC in vivo is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Protein kinase C, an elusive therapeutic target?
Mochly-Rosen, D., Das, K., & Grimes, K. V. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3871 · Cited by 563
Self-citationThe role of mitochondria in protection of the heart by preconditioning
Halestrap, A. P., Clarke, S. J., & Khaliulin, I. (2007) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2007.05.008 · Cited by 390
The role of the mitochondrial permeability transition pore in heart disease
Halestrap, A. P., & Pasdois, P. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.12.017 · Cited by 362
TAT transduction: the molecular mechanism and therapeutic prospects
Gump, J. M., & Dowdy, S. F. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.002 · Cited by 356
Postconditioning: Reduction of reperfusion-induced injury
ZHAO, Z., & VINTENJOHANSEN, J. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.01.024 · Cited by 272
Metadata
- Authors
- Inagaki, K., Begley, R., Ikeno, F., & Mochly-Rosen, D.
- Venue
- Circulation
- Published
- 2005-01-04
- Volume
- 111
- Issue
- 1
- Pages
- 44-50
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2102200534
- Cited by
- 126
- References
- 0
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardioprotection by ε-Protein Kinase C Activation From Ischemia: Continuous Delivery and Antiarrhythmic Effect of an ε-Protein Kinase C-Activating Peptide. https://app.cochat.ai/papers/10.1161/01.cir.0000151614.22282.f1
- The paper
- Inagaki, K., Begley, R., Ikeno, F., & Mochly-Rosen, D. (2005). Cardioprotection by ε-Protein Kinase C Activation From Ischemia: Continuous Delivery and Antiarrhythmic Effect of an ε-Protein Kinase C-Activating Peptide. Circulation. https://doi.org/10.1161/01.cir.0000151614.22282.f1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.